Guorong Xu

Guorong Xu

Auto-generated profile, based on publicly available information

Guorong Xu

Center for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
FGFrederico Omar Gleber-Netto
Frederico Omar Gleber-Netto
XRXiayu Rao
Xiayu Rao
TGTheresa Guo
Theresa Guo
YXYuanxin Xi
Yuanxin Xi
MGMeng Gao
Meng Gao
CPCurtis Pickering
Curtis Pickering
Incidence of HPV + oropharyngeal squamous cell carcinoma (OPSCC) has been increasing dramatically. Although long-term survival rates for these patients are high, they often suffer from permanent radiotherapy-related morbidity. This has prompted the development of de-escalation clinical protocols to reduce morbidity. However, a subset of patients do not respond even to standard therapy and have poor outcomes. It is unclear how to properly identify and treat the high- and low-risk HPV + OPSCC patients. Since HPV positivity drives radiotherapy sensitivity, we hypothesized that variations in HPV biology may cause differences in treatment response and outcome. By analyzing gene expression data, we identified variations in HPV-related molecules among HPV + OPSCC. A subset of tumors presented a molecular profile distinct from that of typical HPV + tumors and exhibited poor treatment response, indicating molecular and clinical similarities with HPV – tumors. These molecular changes were also observed in vitro and correlated with radiation sensitivity. Finally, we developed a prognostic biomarker signature for identification of this subgroup of HPV + OPSCC and validated it in independent cohorts of oropharyngeal and cervical carcinomas. These findings could translate to improved patient stratification for treatment deintensification and new therapeutic approaches for treatment-resistant HPV-related cancer.

28 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
MJMelissa Kaye Jones
Melissa Kaye Jones
DADevansh Agarwal
Devansh Agarwal
KMKevin William Mazo
Kevin William Mazo
MCManan Chopra
Manan Chopra
SJShawna L. Jurlina
Shawna L. Jurlina
KWKarl J. Wahlin
Karl J. Wahlin
Retinogenesis involves the specification of retinal cell types during early vertebrate development. While model organisms have been critical for determining the role of dynamic chromatin and cell-type specific transcriptional networks during this process, an enhanced understanding of the developing human retina has been more elusive due to the requirement for human fetal tissue. Pluripotent stem cell (PSC) derived retinal organoids offer an experimentally accessible solution for investigating the developing human retina. To investigate cellular and molecular changes in developing early retinal organoids, we developed SIX6-GFP and VSX2-tdTomato (or VSX2-h2b-mRuby3) dual fluorescent reporters. When differentiated as 3D organoids these expressed GFP at day 15 and tdTomato (or mRuby3) at day 25, respectively. This enabled us to explore transcriptional and chromatin related changes using RNA-seq and ATAC-seq from pluripotency through early retina specification. Pathway analysis of developing organoids revealed a stepwise loss of pluripotency, while optic vesicle and retina pathways became progressively more prevalent. Correlating gene transcription with chromatin accessibility in early eye field development showed that retinal cells underwent a clear change in chromatin landscape, as well as gene expression profiles. While each dataset alone provided valuable information, considering both in parallel provided an informative glimpse into the molecular nature eye development.

1 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JQJesse Qualliotine
Jesse Qualliotine
TNTakuya Nakagawa
Takuya Nakagawa
SRSara Brin Rosenthal
Sara Brin Rosenthal
SSSayed Sadat
Sayed Sadat
CBCarmen Ballesteros-Merino
Carmen Ballesteros-Merino
JCJoseph A. Califano
Joseph A. Califano
HPV-associated oropharynx carcinoma (HPVOPC) tumors have a relatively low mutational burden. Elucidating the relative contributions of other tumor alterations, such as DNA methylation alterations, alternative splicing events (ASE), and copy number variation (CNV), could provide a deeper understanding of carcinogenesis drivers in this disease. We applied network propagation analysis to multiple classes of tumor alterations in a discovery cohort of 46 primary HPVOPC tumors and 25 cancer-unaffected controls and validated our findings with TCGA data. We identified significant overlap between differential gene expression networks and all alteration classes, and this association was highest for methylation and lowest for CNV. Significant overlap was seen for gene clusters of G protein-coupled receptor (GPCR) pathways. HPV16–human protein interaction analysis identified an enriched cluster defined by an immune-mediated GPCR signal, including CXCR3 cytokines CXCL9, CXCL10, and CXCL11. CXCR3 was found to be expressed in primary HPVOPC, and scRNA-seq analysis demonstrated CXCR3 ligands to be highly expressed in M2 macrophages. In vivo models demonstrated decreased tumor growth with antagonism of the CXCR3 receptor in immunodeficient but not immunocompetent mice, suggesting that the CXCR3 axis can drive tumor proliferation in an autocrine fashion, but the effect is tempered by an intact immune system. In conclusion, methylation, ASE, and SNV alterations are highly associated with network gene expression changes in HPVOPC, suggesting that ASE and methylation alterations have an important role in driving the oncogenic phenotype. Network analysis identifies GPCR networks, specifically the CXCR3 chemokine axis, as modulators of tumor–immune interactions that may have proliferative effects on primary tumors as well as a role for immunosurveillance; however, CXCR3 inhibition should be used with caution, as these agents may both inhibit and stimulate tumor growth considering the competing effects of this cytokine axis. Further investigation is needed to explore opportunities for targeted therapy in this setting.

30 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
COCarlos J. Díaz Osterman
Carlos J. Díaz Osterman
DODuygu Ozmadenci
Duygu Ozmadenci
EKElizabeth G. Kleinschmidt
Elizabeth G. Kleinschmidt
KTKristin N. Taylor
Kristin N. Taylor
ABAllison M. Barrie
Allison M. Barrie
DSDavid D. Schlaepfer
David D. Schlaepfer
Gene copy number changes, cancer stem cell (CSC) increases, and platinum chemotherapy resistance contribute to poor prognosis in patients with recurrent high grade serous ovarian cancer (HGSOC). CSC phenotypes involving Wnt-β-catenin and aldehyde dehydrogenase activities, platinum resistance, and tumor initiating frequency are here associated with spontaneous genetic gains, including genes encoding K RAS , M YC and F AK , in a new murine model of ovarian cancer (KMF). Noncanonical FAK signaling was sufficient to sustain human and KMF tumorsphere proliferation, CSC survival, and platinum resistance. Increased FAK tyrosine phosphorylation occurred in HGSOC patient tumors surviving neo-adjuvant platinum and paclitaxel chemotherapy and platinum resistant tumorspheres acquired FAK dependence for growth. Importantly, combining a pharmacologic FAK inhibitor with platinum overcame chemoresistance and triggered apoptosis in vitro and in vivo . Knockout, rescue, genomic and transcriptomic analyses collectively identified more than 400 genes regulated along a FAK/β-catenin/Myc axis impacting stemness and DNA repair in HGSOC, with 66 genes gained in a majority of Cancer Genome Atlas samples. Together, these results support combinatorial testing of FAK inhibitors for the treatment of recurrent ovarian cancer. Graphical Summary: Key Points: High grade serous ovarian carcinoma tumors contain PTK2 (FAK) 8q24.3 gains associated with prognostic differences. KMF, a new murine ovarian cancer model with K -Ras, M yc, and F AK gene gains and intrinsic platinum resistance. FAK activation in tumors surviving platinum chemotherapy promotes cancer stem cell survival. FAK facilitates a β-catenin-Myc signaling axis controlling gene expression supporting platinum resistance. FAK activity is essential for KMF tumor growth and is a targetable cellular adaptation of platinum resistance.